# US 2002/0160383 A1 · Use of nucleic acid analogues in diagnostics and analytical procedures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160383 A1
- Document ID: US20020160383A1
- Status: Published application
- Kind: A1
- Application number: 09/983,210
- Filed: 2001-10-23
- Published: 2002-10-31
- Earliest claimed: 1991-05-24
- Inventors: Ole Buchardt; Michael Egholm; Peter E. Nielsen; Rolf H. Berg
- Web page: https://patentgrep.com/patent/US20020160383A1

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61P 31/12: Antivirals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/003: {Peptide-nucleic acids (PNAs)}
- C12Q 1/68: involving nucleic acids
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6832: Enhancement of hybridisation reaction
- C12Q 1/6869: Methods for sequencing
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention pertains to certain nucleic acid analogs and related kits that are useful for the capture, recognition, detection, identification, or quantification of certain chemical or biological entities.

## Claims

### Claim 1

A nucleic acid analogue for use in the capture, recognition, detection, identification or quantitation of one or more chemical or microbiological entities, which analogue is
(a) a peptide nucleic acid (PNA) comprising a polyamide backbone bearing a plurality of ligands at respective spaced locations along said backbone, said ligands being each independently naturally occurring nucleobases, non-naturally occurring nucleobases or nucleobase-binding groups, each said ligand being bound directly or indirectly to a nitrogen atom in said backbone, and said ligand bearing nitrogen atoms mainly being separated from one another in said backbone by from 4 to 8 intervening atoms;
(b) a nucleic acid analogue capable of hybridising to a nucleic acid of complementary sequence to form a hybrid which is more stable against denaturation by heat than a hybrid between the conventional deoxyribonucleotide corresponding to said analogue and said nucleic acid; or
(c) a nucleic acid analogue capable of hybridising to a double stranded nucleic acid in which one strand has a sequence complementary to said analogue, so as to displace the other strand from said one strand.

### Claim 2 (depends on 1)

A nucleic acid analogue as claimed in claim 1, having the general formula:
8
wherein:
n is at least 2,
each of L1-Ln is independently selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of A1-An is a single bond, a methylene group or a group of formula:
9
where:
X is O, S, Se, NR3, CH2 or C(CH3)2;
Y is a single bond, 0, S or NR4;
each of p and q is an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more-than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and
each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy- or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each of B1-Bn is N or R3N+, where R3 is as defined above;
each of C1-Cn is CR6R7, CHR6CHR7 or CR6R7CH2, where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio-substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each of D1-Dn is CR6R7, CH2CR6R7 or CHR6CHR7, where R6 and R7 are as defined above;
each of G1-Gn−1 is —CONR3—, —CSNR3—, —SONR3— or —SO2NR3—, in either orientation, where R3 is as defined above;
Q is —CO2H, —CONR′R″, —SO3H or —SO2NR′R″ or an activated derivative of —CO2H or —SO3H; and
I is —NHR′″R″″ or —NR′″C(O)R″″, where R′, R″, R′″ and R″″ are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.

### Claim 3 (depends on 2)

A nucleic acid analogue as claimed in claim 2, having the general formula:
10
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7′ is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60,
each k and m is, independently, zero or one; and each 1 is independently from zero to 5;
Rh is OH, NH2 or —NHLysNH2; and
Ri is H or COCH3.

### Claim 4 (depends on 3)

A nucleic acid analogue as claimed in claim 3, having the general formula:
11
wherein:
each L is independently selected from the group consisting of the nucleobases thymine, adenine, cytosine, guanine, and uracil;
each R7′ is hydrogen; and
n is an integer from 1 to 30.

### Claim 5 (depends on 1, 2, 3, 4)

A nucleic acid analogue as claimed in any one of claims 1 to 4, incorporating or conjugated to a detectable label.

### Claim 6 (depends on 5)

A labelled nucleic acid analogue as claimed in claim 5, wherein said label is a radio isotope label, an enzyme label, biotin, a fluorophore, a chemiluminescence label, an antigen, an antibody or a spin label.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The use of nucleic acid analogue as defined in any one of claims 1 to 6 in the capture, recognition, detection, identification or quantitation of one or more chemical or microbiological entities.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A method of capturing a nucleic acid comprising, contacting under hybridising conditions said nucleic acid with a nucleic acid analogue as claimed in any one of claims 1 to 6 immobilised to a solid support, which nucleic acid analogue has a sequence of ligands suitable to hybridise to said nucleic acid.

### Claim 9 (depends on 8)

A method as claimed in claim 8, wherein said captured nucleic acid is detected, recognised, quantitated or identified by treatment with a nucleic acid recognition agent whilst bound to said immobilised nucleic acid analogue.

### Claim 10 (depends on 9)

A method as claimed in claim 9, wherein the captured nucleic acid has a first region hybridised to said immobilised nucleic acid analogue and a second region which is not so hybridised and is treated with a labelled nucleic acid or nucleic acid analogue which is adapted to hybridise to at least part of said second region and said label is detected.

### Claim 11 (depends on 8)

A method as claimed in claim 8, for capturing a mRNA wherein said immobilised nucleic acid analogue comprises sequential ligands hybridisable to poly A tails of said mRNA to capture said mRNA.

### Claim 12 (depends on 11)

A method as claimed in claim 11, wherein said sequential ligands are thymine.

### Claim 13 (depends on 8, 11, 12)

A method as claimed in-any one of claims 8 or 11 or 12, wherein said nucleic acid once captured is released from said immobilised nucleic acid analogue by subjecting the immobilised nucleic acid analogue and captured nucleic acid to dehybridising conditions.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6)

A nucleic acid analogue as claimed in any one of claims 1 to 6 immobilised to a solid support.

### Claim 15 (depends on 14)

An immobilised nucleic acid analogue as claimed in claim 14, incorporated in an affinity capture column.

### Claim 16 (depends on 5, 6)

A method of recognition, detection or quantitation of a target nucleic acid comprising hybridising said target to a labelled nucleic acid analogue as claimed in claim 5 or claim 6 of sufficiently complementary sequence to hybridise therewith under hybridising conditions and detecting or quantitating said label of the nucleic acid analogue so hybridised to said target.

### Claim 17 (depends on 16)

A method as claimed in claim 16, wherein said target nucleic acid is immobilised on a substrate prior to said hybridisation.

### Claim 18 (depends on 17)

A method as claimed in claim 17, wherein said target nucleic acid is immobilised to said substrate by the hybridisation of a first region thereof to a capture nucleic acid or nucleic acid analogue having a sequence sufficiently complementary to said first region to hybridise therewith and which is itself immobilised to said substrate and wherein said labelled nucleic acid analogue hybridises to a second region of said target.

### Claim 19

A method for displacing one strand from a nucleic acid duplex comprising hybridising to said duplex a nucleic acid analogue having an affinity for the other strand of said duplex sufficient to be able to displace said one strand therefrom.

### Claim 20

A method of detecting, identifying or quantitating a double stranded target nucleic acid comprising hybridising thereto a displacing nucleic acid analogue capable of displacing one strand from a double stranded target in which the other strand is of complementary sequence to said displacing nucleic acid analogue, wherein said displacing nucleic acid analogue is of sufficiently complementary sequence to said other strand of said double stranded target to hybridise thereto so as to displace said one strand of said target in single stranded form, and detecting or quantitating the presence of said one displaced strand.

### Claim 21 (depends on 20)

A method as claimed in claim 20, wherein the displaced strand is broken down into fragments and the presence of said fragments is detected.

### Claim 22 (depends on 21)

A method as claimed in claim 21, wherein said displaced strand is broken down by attack by a nuclease.

### Claim 23 (depends on 5, 6)

A kit for use in a diagnostics procedure and comprising at least one labelled nucleic acid analogue as claimed in claim 5 or claim 6, and at least one detection reagent for detecting said labelled nucleic acid analogue.

### Claim 24 (depends on 1, 2, 3, 4, 23)

A kit as claimed in claim 23, further including a nucleic acid analogue as claimed in any one of claims 1 to 4 immobilised on a solid support.

### Claim 25 (depends on 1, 2, 3, 4)

A kit comprising an immobilised nucleic acid analogue as claimed in any one of claims 1 to 4, in combination with at least one nucleic acid recognition agent for detecting the presence of nucleic acid captured in use by said nucleic acid analogue.

### Claim 26 (depends on 25)

A kit as claimed in claim 25, wherein said nucleic acid recognition agent is a labelled nucleic acid or a labelled nucleic acid analogue.
